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Abstract (246 words)  26 
Drug resistance testing, or antimicrobial susceptibility testing (AST), is mandatory for 27 
Mycobacterium tuberculosis (MTB) in cases of failure to standard therapy. We reviewed the 28 
different methods and techniques of phenotypic and genotypic approaches. Although Multi- 29 
and extensively- drug resistant (MDR-XDR) tuberculosis is present worldwide, AST-MTB is 30 
still mainly performed according to the resources available rather than the drug resistance 31 
rates. Phenotypic methods, i.e., culture based AST, are commonly used in high income 32 
countries to confirm susceptibility of new cases of tuberculosis. They are also performed to 33 
detect resistance in tuberculosis cases with risk factors, in combination with genotypic tests. 34 
In low income countries, genotypic methods screening hot spot mutations known to confer 35 
resistance, were found to be easier to perform because they avoid the culture and biosafety 36 
constraint. Given that genotypic tests can rapidly detect the prominent mechanisms of 37 
resistance, such as the rpoB mutation for rifampicin resistance, we are facing new challenges 38 
with the observation of false-resistance (mutations not conferring resistance) and false-39 
susceptibility (mutations different from the common mechanism) results. Phenotypic and 40 
genotypic approaches are thus complementary for obtaining a high sensitivity and specificity 41 
for detecting drug resistances and susceptibilities to accurately predict MDR/XDR cure and to 42 
gather relevant data for resistance surveillance. Although AST-MTB was established in the 43 
1960s, there is no consensus reference method for MIC determination against which the 44 
numerous AST-MTB techniques can be compared. This information is necessary for 45 
assessing the in vitro activity and setting breakpoints for future anti-tuberculosis agents.  46 
 47 
Keywords: Antimicrobial susceptibility testing, genetic resistance, critical concentration, 48 
critical proportion, MIC, hot spot mutations 49 
 50 
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Objectives – definitions - history of drug resistance testing in tuberculosis  51 
Drug resistance testing (DRT) for Mycobacterium tuberculosis (MTB) has two objectives: (i) 52 
individual management (treatment and prevention) of tuberculosis (TB) cases and (ii) anti-TB 53 
drug resistance surveillance. Since the first use of anti-TB drugs in the late 1940s [1], relapse 54 
cases of tuberculosis with acquired resistance have been repeatedly observed for all new 55 
effective drugs [2-4]. Because the resistant strains were then transmitted to treatment-naïve 56 
patients, DRT for MTB was recommended for all definite cases of tuberculosis [5]. Multi-57 
drug resistant (MDR) TB, defined as resistance to the two key drugs isoniazid and rifampicin, 58 
has emerged as a global threat and occurs more frequently in previously treated cases 59 
(secondary resistance) than in untreated patients (primary resistance) [6]. However, DRT was 60 
estimated to be performed in only 58% of previously treated TB cases (12% of untreated 61 
cases), and DRT is mostly done in high income countries where the resistance rates are the 62 
lowest [6].  63 
 Because the criteria for drug resistance in MTB were defined in patients with treatment 64 
failure (clinical resistance) [7,8], the so-called “resistant” MTB strain is unlikely to show 65 
clinical responsiveness to the drug, and conversely, the “susceptible” MTB strain is likely to 66 
show response to treatment. Acquired resistance in MTB was suspected to be due to the 67 
selection of resistant mutants because similar mutants were observed in wild-type strains as 68 
pre-existing mutants. However, these mutants were present in lower proportions in previously 69 
untreated patients (e.g., 1/105 for isoniazid, 1/108 for rifampicin) than in the relapsed TB cases 70 
where proportions ranging from 1/102 (1%) to 1/1 (100%) have been observed [7]. Genetic 71 
confirmation of this phenomenon was obtained when point mutations conferring resistance 72 
were observed in strains isolated from patients with treatment failure [9,10]. Major advances 73 
in laboratory methods for drug resistance testing were achieved in the 1960s when TB was 74 
endemic to western countries [11]. However, the testing methods have not changed much 75 
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since then and remain isolated to specialized laboratories, even at a time when detection of 76 
resistance for other bacteria, such as staphylococci and gram-negative bacilli, has been well 77 
organized by national and international committees such as European Committee on 78 
Antimicrobial Susceptibility Testing (EUCAST). Consequently, drug resistance testing in 79 
MTB appears today as using “old school” methods [5].  80 
 Although phenotypic culture based methods were first designed to detect drug 81 
resistance, there is an increasing need for the development of antimicrobial susceptibility 82 
testing (AST) as is done for other bacteria according to the principles created by the 83 
EUCAST. In 2016, there is no universal reference method for AST-MTB, which is 84 
challenging when setting the clinical reference points for old as well as new drugs, including 85 
bedaquiline and delamanid [12]. Additionally, any evaluation of potential drug resistance 86 
mutations using whole genome sequencing (WGS) data is heavily dependent on a uniform 87 
and well-defined reference method for AST-MTB.  88 
 89 
Phenotypic methods and challenges for predicting resistance  90 
In 1969, drug resistance in MTB was defined as “a decrease in the sensitivity of sufficient 91 
degree to be reasonably certain that the strain concerned is different from wild-type strains, 92 
which are isolates that have never come into contact with the drug”. Isolates that cannot grow 93 
at “critical” concentrations were then defined as susceptible, whereas those that can grow 94 
were considered resistant. This was the rationale for the resistance ratio method described by 95 
Mitchison [13] and the proportion method described by Canetti [7]. However, Canetti showed 96 
that in wild-type strains, there was a certain proportion of resistant mutants pre-existing in the 97 
tubercle bacillus population and calculated that a proportion of 1% was the higher limit 98 
between the susceptible and resistant isolates [7]. The AST-MTB techniques used today are 99 
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based on these two methods with some techniques considering only the critical concentration 100 
or both the critical concentration and the critical proportion (Table 1) [7,8,14]. 101 
One of the most discussed points in relation to AST-MTB is the “critical 102 
concentration” (CC), i.e., the drug concentration (in mg/L or µg/ml) included in the culture 103 
medium. These concentrations were not based on pharmacokinetics/pharmacodynamics 104 
(PK/PD) but were determined experimentally by comparing the growth of wild-type versus 105 
“non” wild-type strains [7]. One should be aware that CC varies with the medium used (egg-106 
based media, such as Löwenstein-Jensen, which are cooked at 80°C, and synthetic 107 
Middlebrook [7H9, 7H10, 7H11 or 7H12] media to which oleic acid albumin, dextrose and 108 
catalase [OADC] are added) because this value depends on the concentration of the drug that 109 
remains active in the media (Table 2).  110 
The challenges for research and development of new DRT or AST techniques are 111 
reducing the time to results and producing easy-to-perform kits. There is also a necessity to 112 
reconsider breakpoints or discuss the need in reporting MICs to improve clinical relevance of 113 
DST results The new tests are limited by the complexity of the resistance development 114 
process in MTB. This process involves dynamic emergence of spontaneous mutants and their 115 
stability with regard to the selective pressure, which is based on PK variability dependent 116 
within the treatment regimen and the patient [15]. One recently developed technique uses the 117 
MGIT 960TB system EpiCenter software equipped with the TB eXiST module (Becton, 118 
Dickinson and Company, New Jersey, USA). This enables simultaneous testing of different 119 
drug concentrations on different bacterial inocula with “real time” visualization of the results 120 
(Fig. 1). This technical improvement is worthwhile for personalized therapeutic purposes and 121 
may have an impact on the cure rate of MDR/XDR-TB infected patients as well as on the 122 
prevention of acquired resistance [16,17]. TB eXiST AST is also used to quantify the 123 
resistance level and may be important for some drugs (see below) [16,18].  124 
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 125 
Minimum inhibitory concentrations in relation to resistant and susceptible 126 
populations of M. tuberculosis 127 
In light of the increasing rates of drug resistance, a modernized approach for setting clinical 128 
AST breakpoints is needed to optimize treatment decisions [19]. According to EUCAST, 129 
clinical breakpoints should be defined by combining minimal inhibitory concentration (MIC) 130 
distributions, clinical outcomes and PK/PD data [19,20]. As described above, MTB 131 
breakpoints were mainly based on experimental data using different media, techniques and 132 
drugs. Most of all, there were no predefined dosing standards, and precise documentation of 133 
previous experiments is mainly inaccessible [19,21,22]. In general, phenotypic AST methods 134 
have the advantage of being able to quantitatively predict not only resistance but also 135 
susceptibility [15,16,20]. However, several obstacles exist for large-scale MIC determination 136 
for MTB as it demands resources, time and biosafety precautions. No MIC reference method 137 
is universally accepted for MTB, and several AST techniques are used (Table 2) [21].  138 
The epidemiological cut-off (ECOFF) is outlined by the Gaussian distribution formed 139 
when MICs are compiled from several laboratories using the same method or technique [20]. 140 
By definition, the ECOFF is the highest MIC for organisms devoid of phenotypically 141 
detectable resistance (the wild-type distribution). For antimicrobial agents considered 142 
clinically active for the organism, the ECOFF is also the lowest possible susceptibility 143 
breakpoint [20]. The ECOFF is the cornerstone for validating rapidly emerging whole genome 144 
sequencing data and for defining clinical breakpoints but has not been systematically used to 145 
define breakpoints for MTB [19,20]. To illustrate MIC distributions (references outlined in 146 
the supplementary reference file), the MIC data for rifampicin were compiled from several 147 
studies including commonly used methods (Fig. 2). The MIC distribution shows a clearly 148 
visible separation between resistant and susceptible populations (Fig. 2A). For the 149 
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fluoroquinolones (FQ), most MIC data is currently available for ofloxacin as a class 150 
representative (Fig. 2B), but clearly there is a need to define ECOFFs for newer FQs, such as 151 
moxifloxacin. There are several examples where the determination of ECOFFs could help in 152 
providing rational breakpoints for MTB [19,23,24].  153 
As genotyping detection of resistance is increasingly used, drug resistance mutations 154 
are reported as associated with a low increase in MICs, which tend to be close to the ECOFFs. 155 
There are several examples where ECOFFs could improve breakpoints for MTB. For 156 
ethambutol, the current breakpoint and the ECOFF are very close to the MICs of isolates with 157 
resistance mutations, such as in codon 306 of embB [23,25]. This might be the reason for the 158 
poor reproducibility of ethambutol testing even among reference laboratories. Recent data 159 
indicated that isolates harbouring some rare specific mutations in codons 516, 526 and 533 of 160 
rpoB may show only a low level rifampicin resistance or even be classified as susceptible in 161 
BACTEC 960 MGIT [26,27]. For rifabutin, the current breakpoint from the Clinical and 162 
Laboratory Standards Institute (CLSI) categorizes non-wild-type isolates with rpoB mutations 163 
in D516V and rifampicin resistance as rifabutin susceptible, without having systematically 164 
evaluated PK/PD and clinical outcome data [21,24]. Such isolates harbouring these resistance 165 
mutations may be identified and separated from wild-type isolates by introducing an 166 
intermediate category since increased dosing of rifampicin is promising according to recent 167 
clinical trials [28]. For fluoroquinolones, ECOFFs are also useful for identifying low level 168 
resistance, such as in codon 90 of gyrA, where MICs can be lower than current breakpoints 169 
[23, 29] but above the ECOFF [30] (Fig. 2B). In contrast to rifampicin, there is a close 170 
relationship between MICs for the susceptible and resistant populations where there may be a 171 
selection bias in favour of resistant isolates, which is important to consider when MIC 172 
distributions for MTB drugs are evaluated (Fig. 2B). For some of the drug resistance 173 
mutations, poorly defined breakpoints result in oscillating AST reports between susceptibility 174 
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and resistance, which may negatively affect clinical management in difficult-to-treat patients 175 
with MDR/XDR-TB and introduce bias in studies comparing genotypic and phenotypic 176 
resistance. It may be possible that such isolates, commonly referred to as having low-level 177 
resistance, are accessible for treatment using optimized dosing and therapeutic drug 178 
monitoring (TDM) [29,30]. However, PK/PD and clinical outcome data need to be 179 
investigated in clinical studies in order to confirm this hypothesis. An intermediate category, 180 
which indicates that such isolates may be treatable with increased dosing and TDM, should be 181 
considered, as is currently the case for other bacterial pathogens, to separate wild-type, fully 182 
susceptible isolates from those with resistance mutations [20]. Inadequate dosing given for 183 
patients with low level resistant isolates erroneously classified as susceptible may lead to poor 184 
treatment outcomes and further development of resistance [30]. 185 
 186 
Genotypic resistance 187 
The vast majority of drug resistance in the Mycobacterium tuberculosis complex is caused by 188 
single-nucleotide-polymorphisms, although insertions or deletions are also possible [31]. 189 
Therefore, molecular assays represent a valuable option to accelerate the detection of 190 
resistance from weeks to hours or days. A variety of techniques have been proposed to detect 191 
resistance mutations, which has resulted in the development of more than 30 commercial 192 
drug-susceptibility assays [32]. Thus far, only line probe assays (LiPAs) and the Xpert 193 
MTB/RIF assay (Cepheid, Sunnyvale, CA) have been endorsed by the World Health 194 
Organization (WHO) for the rapid detection of MDR tuberculosis cases [33]. Several 195 
commercial tests are available to detect rifampicin resistance including InnoLipa RIF-TB, 196 
GenoType MTBDRplus, AID test and the LiPA Nipro NTM+MDRTB assay, and all of these 197 
tests, except the InnoLipa RIF-TB, also detect mutations that confer resistance to isoniazid 198 
[34-36]. 199 
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LiPAs are based on the targeted amplification of specific regions of the M. 200 
tuberculosis genome followed by hybridization of the amplicons to oligo probes immobilized 201 
on nitrocellulose strips. They were the first genotypic tests used to detect MDR-MTB in the 202 
1990s, by detecting rpoB mutations in the rifampicin resistance-determining region (RRDR) 203 
[37]. The pooled sensitivity of the GenoType MTBDRplus (version 1) for the detection of 204 
rifampicin resistance was found to be 98.1% (95% CI 95.9-99.1) with a specificity of 98.7% 205 
(95% CI 97.3-99.4). The results for isoniazid showed a lower sensitivity (84.3%, 95% CI 206 
76.6-89.8) but a high specificity (99.5%, 95% CI 97.5-99.9) [35]. More recently, non-207 
inferiority of version 2 of the GenoType MTBDRplus assay and the newly developed LiPA 208 
Nipro NTM+MDRTB assay was demonstrated [36]. Among real time PCR assays, the 209 
Cepheid Gene Xpert MTB/RIF, a fully automated real time PCR-based assay for the detection 210 
of M. tuberculosis DNA and mutations associated with rifampicin resistance, has a pooled 211 
sensitivity and specificity of 95% (95% CI 90-97) and 98% (95% CI 97-99), respectively 212 
[33,38,39]. Because this test requires less technical expertise, the Xpert MTB/RIF is today 213 
widely used, and some countries have even decided to use it as the initial diagnostic test for 214 
patients with presumptive TB.  215 
Overall, the sensitivity of the genotypic tests for the detection of rifampicin resistance 216 
(a surrogate marker for detecting MDR-MTB) is generally over 95-98% [33,36,38,39], which 217 
shows that most of the resistant isolates harbour rpoB mutations located in the RRDR. The 218 
specificity is also generally close to 99% [33,36,38,39], which shows that most rpoB 219 
mutations found in the RRDR confer resistance. However, since the practice of genotypic 220 
testing has greatly increased during the last five years, rpoB mutations not associated with 221 
resistance are now being detected, which brings the genotype-phenotype correlation into 222 
question [40]. The Cochrane review performed in 2014 nicely showed that although the 223 
performances of these tests are excellent, one should calculate the predictive values for 224 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
resistance and susceptibility detection according to the resistance rate measured at the scale of 225 
the country, region or city [39].  226 
For second line drug detection, especially for detecting XDR isolates, there is no fully 227 
automated point-of-care assay thus far. The WHO recently endorsed the GenoType MTBDRsl 228 
version 2 LiPA for the detection of resistance to fluoroquinolones (mutations in gyrA and 229 
gyrB quinolone resistance-determining regions) and to kanamycin, amikacin, and 230 
capreomycin (mutations at the rrs 1401-1402 positions and in the eis gene promoter) [41]. 231 
The results from the aforementioned assays have to be analysed with care. First, they 232 
can generally only be used to rule-in, as opposed to rule-out resistance given that they target a 233 
limited number of known resistance mutations. Second, systematic false-positive results are 234 
possible due to synonymous mutations, which can significantly affect the positive predictive 235 
values in settings where the true rate of resistance is low [42]. Third, the interpretation of their 236 
results is not always clear, such as the degree of cross-resistance to fluoroquinolones caused 237 
by particular gyrA mutations [26,29]. Additional research is therefore urgently required to 238 
address these shortcomings in our understanding of resistance on the genotypic as well as 239 
phenotypic level. 240 
 241 
Gaps, challenges and prospective research  242 
Over the past few years, steady progress has been made in elucidating novel resistance 243 
mechanisms, particularly for second-line drugs [4,43]. However, it is important to appreciate 244 
that the remaining discrepancies between genotypic and phenotypic results are not solely due 245 
to yet unknown resistance mechanisms [15,16]. Instead, factors such as the aforementioned 246 
shortcomings with the current critical concentrations, primary versus acquired resistance, the 247 
inadequate limits-of-detection of sequencing, random errors, and false associations between 248 
genotype and phenotype all play a role. 249 
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The relative importance of these factors differs among antibiotics and has to be 250 
dissected in carefully designed studies. For example, it is becoming increasingly clear that 251 
hetero-resistant mutations that occur at less than approximately 30% of the total population 252 
and are therefore not detected by Sanger sequencing play an important role in resistance to 253 
fluoroquinolones [16,44,45]. This inadequate limit-of-detection provided by Sanger 254 
sequencing to detect low-level hetero-resistance compared with phenotypic methods, which 255 
can be calibrated to detect resistance at 1% of the population for most drugs, can be overcome 256 
by either sequencing from the drug-containing medium (as opposed to the drug-free medium 257 
from which sequencing is usually performed) or by increasing the sequencing coverage. It 258 
should be noted, however, that even at high coverage current bioinformatics algorithms do not 259 
necessarily identify hetero-resistant insertions or deletions. 260 
Random errors (i.e., usually false-resistant results) are an important factor for drugs 261 
for which the true prevalence of resistance is low. Therefore, repeating phenotypic and 262 
genotypic testing for discrepant results is warranted to identify candidate isolates with novel 263 
resistance mechanisms [46]. Finally, it is important to include large numbers of genotypically 264 
diverse susceptible control isolates to avoid false-associations between a resistant phenotype 265 
and mutations that are merely polymorphisms, as discussed elsewhere in more detail [42]. In 266 
this context, it is notable that the general assumption that resistance mutations confer 267 
resistance irrespective of their genetic background may not always apply, although the clinical 268 
relevance of these observations remains to be determined [47,48]. For example, whiB7 269 
mutations do not result in streptomycin resistance in isolates with an inactive Tap efflux 270 
pump, an underestimated physiological mechanism of resistance in MTB, which underlines 271 
the need for a detailed and broad-ranged mechanistic understanding of resistance mechanisms 272 
in MTB [43]. 273 
 274 
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Conclusions and perspectives 275 
Phenotypic AST is still the most reliable laboratory approach to determine antimicrobial 276 
resistance and susceptibility in MTB, its advantages being quality control networks and 277 
generally good clinical correlation [49]. Advantages of genotypic methods include the ability 278 
to easily and rapidly detect resistance, but there are still limitations regarding the accuracy 279 
(needs for robust quality control) and the correlation with treatment and clinical outcome 280 
because only some mutations have been demonstrated to consistently and reliably confer 281 
high-level resistance [25]. The discrepancies between genotype and phenotype AST 282 
approaches, which are limited to certain antibiotics and certain isolates [27,50], need to be 283 
solved by more research into resistance mechanisms. Because of the spread of drug resistance 284 
in MTB, patients with MDR-TB and XDR-TB infections should have the chance of being 285 
treated on the basis of antibiotic resistance profiles as determined by combined phenotypic 286 
and genotypic methods. Because there is good news about the development of new anti-TB 287 
drugs for the next decades, we must reach a consensus for a reference method according to the 288 
new standards of EUCAST in a timely fashion. This is one important goal of the newly 289 
formed EUCAST subcommittee on antimycobacterial susceptibility testing 290 
(http://www.eucast.org/mycobacteria/). 291 
 292 
Transparency declarations 293 
No conflicts of interest are declared for the submitted work, with the exception of Dr Köser 294 
who is a consultant for the Foundation for Innovative New Diagnostics. The Bill & Melinda 295 
Gates Foundation and Janssen Pharmaceutica covered Dr Köser’s travel and accommodation 296 
to present at meetings.  297 
 298 
Funding: No specific funding 299 
  300 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
TABLE 1. Phenotypic methods and techniques used for drug susceptibility testing in 301 
Mycobacterium tuberculosis [14] 302 
Methods Detection of MTB growth 
 Direct evidence Indirect evidence 
Critical concentration Resistance ratio  
Absolute concentration 
Microscopy observed direct 
susceptibility testing 
(MODS) 
Microtitre plates (e.g., 
Versatrek) 
Nitrate reductase assay 
Resazurin test 
Alamar blue test 
Critical proportion and 
critical concentrations 
WHO and ECDC 
recommended protocol on 
Löwenstein Jensen 
CLSI recommended protocol 
on 7H10 or 7H11 
Automated BACTEC 
MGIT960 
 
 303 
  304 
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TABLE 2. Critical concentrations (mg/L) used in various techniques of antimicrobial 305 
susceptibility testing for Mycobacterium tuberculosis [14,16,21] 306 
Antimicrobial 
agent 
 
LJ 7H11  7H10 MGIT MGIT TB eXiST qAST 
     Low Intermediate High 
Isoniazid  0.2 0.2 0.2 0.1 0.1 1-3 10 
Rifampicin  40 1.0 1.0 1.0 1 4 20 
Ethambutol  2.0 7.5 5.0 5.0 5 12.5 50 
Streptomycin  4.0 2.0 2.0 1.0 1 4 20 
Kanamycin  30 6.0 5.0 2.5 - - - 
Amikacin  30 - 4.0 1.0 1 4 20 
Capreomycin  40 - 4.0 2.5 2.5 5 25 
Ofloxacin  4.0 2.0 2.0 2.0 1 2 10 
Moxifloxacin 
 
0.5 - 0.5/2 0.5/2 0.25 0.5 2.5 
 307 
  308 
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Figure legends 309 
FIG. 1. Representative results for quantitative resistance testing using the MGIT-TB eXiST 310 
technique performed for a M. tuberculosis isolate showing a low level resistance to 311 
moxifloxacin (R at 0.25 but S at 0.5 mg/L) and harbouring a gyrA A90V mutation. 312 
The growth in control tubes appears as blue lines (dotted line for 1:1; discontinuous line for 313 
1:10 and continuous line for 1:100). Resistance was detected as growth appearing in the tube 314 
containing 0.25 mg/L (pink line) at the same time (14 days) as the 100% inoculum, but 315 
growth at 0.5 mg/L (green line) was observed only after the 1% inoculum.  316 
 317 
FIG. 2 MIC distributions for (A) rifampicin (395 isolates from 7 studies in 7H10, 7H11 and 318 
MGIT) and (B) ofloxacin (2538 isolates from 22 studies in 7H10, 7H11, MGIT, 7H9 and LJ). 319 
The references are listed in the supplementary files. The PubMed search strategies (until the 320 
31st of May 2016) were “rifampicin” AND “Mycobacterium tuberculosis” AND “MIC” for 321 
rifampicin MIC data, and “ofloxacin” or “fluoroquinolones” AND “Mycobacterium 322 
tuberculosis” for ofloxacin MIC data. Abbreviations: 7H10, Middlebrook 7H10 media; 323 
MGIT, BACTEC 960 MGIT media; 7H11, Middlebrook 7H11 media; 7H9, Middlebrook 324 
7H9 media; LJ, Löwenstein-Jensen media. 325 
 326 
 327 
Supplementary FIG.1  PRISMA flow charts for searches on MIC data for (A) rifampicin and 328 
for (B) ofloxacin 329 
  330 
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